Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The companies say BioArctic will develop a new therapy candidate by pairing its BrainTransporter drug-delivery platform with a molecule from Lilly, aiming at targets in the neurodegenerative space.
THE APEX TIMES
THE APEX TIMES
A Yahoo Finance roundup ranks Eli Lilly and Company’s LLY shares among stocks it describes as aligned with longevity and anti-aging themes, pointing to a relatively low short position in the stock and grouping it with other companies working in the broader healthspan space.
THE APEX TIMES
The Swedish biotech BioArctic said it has entered a research and collaboration agreement with Eli Lilly to explore a potential new therapy that pairs an undisclosed Lilly compound with BioArctic’s BrainTransporter™ delivery platform.
THE APEX TIMES
The Swedish biotech said it has started a research and collaboration effort with Eli Lilly aimed at exploring a potential new treatment that combines Lilly’s compound with BioArctic’s BrainTransporter™ technology.
THE APEX TIMES
A recent Yahoo Finance market note framed a central question for Eli Lilly’s stock after a strong 12-month run: does the market price still line up with what the business is worth?
THE APEX TIMES
A new market column argues Pfizer’s much higher dividend yield versus Eli Lilly could draw income-focused investors even as the market questions Pfizer’s near-term outlook.
THE APEX TIMES
A flurry of seven deals over roughly three months is positioning Eli Lilly to expand multiple parts of its drug development pipeline at once, according to a new market-focused report.
THE APEX TIMES
A market commentary published June 20 frames Eli Lilly’s outlook as resilient, even as the drugmaker has faced challenges over the past year.
THE APEX TIMES
A Yahoo Finance report says Vertex already has a head start in non-opioid pain, while Eli Lilly has spent billions to catch up, raising the prospect that the companies could compete more directly than they do today.
